Navigation Links
Endo Pharmaceuticals Returns Product Rights to TRANSDUR(TM)-Sufentanil to DURECT
Date:2/27/2009

CUPERTINO, Calif., Feb. 27 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) today reported that Endo Pharmaceuticals (Nasdaq: ENDP) has given notice that it is returning to us Endo's rights in the U.S. and Canada to develop and commercialize TRANSDUR(TM)-Sufentanil, a proprietary transdermal patch in development intended to treat chronic pain. Endo and DURECT recently completed a successful end-of-Phase II meeting with the FDA. Endo has notified us of its intention to terminate the license agreement entered into between Endo and DURECT, and has committed to assist in an orderly and rapid transition of this program back to DURECT.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

"We are disappointed to lose Endo as a partner for the U.S. and Canada, but understand that the program is no longer a strategic fit for them," stated James Brown, President and CEO of DURECT. "However, we appreciate the fact that Endo substantially advanced this program such that it is now Phase III ready. With the worldwide rights to this program restored to us, we believe we have an attractive asset to partner or to progress it ourselves."

Endo recently successfully completed a Phase II program for TRANSDUR- Sufentanil in which they evaluated the conversion of patients on oral and transdermal opioids to TRANSDUR-Sufentanil. The most recent Phase II study met its primary and secondary objectives of establishing a successful dose- titration regimen and dose potency relationships, demonstrating safety and tolerability at the therapeutic dose, and achieving effective analgesic pain control. The Phase II data, extensive non-clinic
'/>"/>

SOURCE DURECT Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... York, New York (PRWEB) August 27, 2014 ... be filed in U.S. courts on behalf of women ... to uterine morcellation, Bernstein Liebhard LLP reports. According to ... filed on August 18th in the U.S. District Court, ... hysterectomy patient who claims the use of a power ...
(Date:8/27/2014)... 27, 2014 When Jagger was 20 years ... his mother; one that he credits as one of the ... had news that she could set him up with a ... disabilities. Jagger took that job, and he has now spent ... past two decades, he also worked in school boards, employment ...
(Date:8/27/2014)... Amy Norton HealthDay Reporter ... who take part in clinical trials of new heart disease ... patient, a new study confirms. Experts said the findings, ... American Medical Association , aren,t surprising -- but they are ... enrolling a more select patient population that is not fully ...
(Date:8/27/2014)... spending for commercially insured individuals is due primarily to ... use, according to a new study led by researchers ... Practice, published in the August issue of the ... increasing concern that consolidation in the health care marketplace ... ultimately, consumers," said Carrie Colla, PhD, assistant professor at ...
(Date:8/27/2014)... Scientists at The Scripps Research Institute (TSRI) have ... can be associated with alcohol dependence. , This ... type 1 (Nf1), which TSRI scientists found is linked ... Nf1 regulates gamma-aminobutyric acid (GABA), a neurotransmitter that lowers ... novel and seminal study provides insights into the cellular ...
Breaking Medicine News(10 mins):Health News:Power Morcellator Lawsuit Alleges Storz Morcellator Caused Spread of Aggressive Uterine Cancer, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Lawsuit Alleges Storz Morcellator Caused Spread of Aggressive Uterine Cancer, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Lawsuit Alleges Storz Morcellator Caused Spread of Aggressive Uterine Cancer, Bernstein Liebhard LLP Reports 4Health News:Fitness on the Go Expands into Liberty Village, City Place and Harbourfront Communities 2Health News:Fitness on the Go Expands into Liberty Village, City Place and Harbourfront Communities 3Health News:Fitness on the Go Expands into Liberty Village, City Place and Harbourfront Communities 4Health News:Heart Studies Don't Reflect Real-World Patients, Study Finds 2Health News:Heart Studies Don't Reflect Real-World Patients, Study Finds 3Health News:Tracking spending among the commercially insured 2Health News:Scripps Research Institute scientists link alcohol-dependence gene to neurotransmitter 2
... could deter more than 100,000 Californians from enrolling in ... today by the California Pan-Ethnic Health Network, the UCLA ... Center for Labor Research and Education. ... that estimates the likely enrollment in health care reform ...
... , WEDNESDAY, Feb. 29 (HealthDay News) -- Federal ... helped provide guidance on whether it,s safe or effective for ... The Institute of Medicine (IOM) report noted, however, ... drugs in newborns or the long-term effects of drugs on ...
... people with diabetes could be adapted into a home DNA ... and bacteria in human body fluids, in food and in ... report on this adaptation of the ubiquitous personal glucose monitor, ... journal Analytical Chemistry . Yi Lu and Yu ...
... (FDA) announced it is revising safety information on the labels ... class of drugs that work in the liver to prevent ... at lowering the LDL (bad) cholesterol, but also have modest ... cholesterol. High cholesterol is a risk factor for ...
... HealthDay Reporter , TUESDAY, Feb. 28 (HealthDay News) ... emergency room with fevers are making the right decision, ... not be generalized, and therefore not approached, as a ... Dr. Yvette van Ierland, from the department of pediatrics ...
... , TUESDAY, Feb. 28 (HealthDay News) -- Taking the ... fetus and lead to poorer motor control in infants, a ... their substance-abuse history before and during pregnancy. The women were ... Infancy Study, which looks at recreational drug use among pregnant ...
Cached Medicine News:Health News:Study: Over 100,000 Californians likely to miss out on health care due to language barriers 2Health News:Efforts to Improve Research on Kids' Drugs Paying Off: Report 2Health News:American Heart Association comment: FDA announces safety changes on labeling for some statins 2Health News:Parents Often Right to Bring Kids With Fever to the ER: Study 2Health News:Parents Often Right to Bring Kids With Fever to the ER: Study 3Health News:Ecstasy Use During Pregnancy May Harm Fetus: Study 2
(Date:8/27/2014)... REDWOOD CITY, Calif. , Aug. 27, 2014 ... in emergency response system design, blended emergency medical ... for CPR/AED (automated external defibrillator) training from the ... and the Army Reserve 81 st ... Homeland Security and Investigations contract includes nationwide CPR/AED/First ...
(Date:8/27/2014)... WARSAW, Ind. , Aug. 27, 2014  Zimmer ... in musculoskeletal care, announced that it will be participating ... the Grand Hyatt in New York, New ... David Dvorak , President and CEO of Zimmer, will ... Binder , President and CEO of Biomet, will join ...
(Date:8/27/2014)... Aug. 27, 2014 Asterias Biotherapeutics Inc. (OTCBB: ... Drug Administration (FDA) to initiate a Phase 1/2a clinical ... cervical spinal cord injury.  The approved trial follows the ... the product, and is designed to assess safety and ... complete cervical spinal cord injuries, the first targeted indication ...
Breaking Medicine Technology:Emergency University Equips Homeland Security, Army Reserve with SCA Response Program to Save Lives of Sudden Cardiac Arrest Victims 2Emergency University Equips Homeland Security, Army Reserve with SCA Response Program to Save Lives of Sudden Cardiac Arrest Victims 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 2Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 4Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 5
... 3, 2007 - Insmed Inc.,(Nasdaq:INSM) today announced positive ... company's drug, IPLEX(TM), in,patients with myotonic muscular dystrophy ... conducted at,the University of Rochester School of Medicine ... doses of IPLEX up to 1,mg/kg/day in six ...
... Ferret Study to be Part of Data Package ... 2007 /PRNewswire-FirstCall/ -- Novavax,Inc. said today that it ... challenge to ferrets inoculated with its pandemic,influenza vaccine, ... on,schedule later this year. , In the study, ...
Cached Medicine Technology:Insmed Announces Promising Results From IPLEX Phase II Myotonic,Muscular Dystrophy Clinical Study 2Insmed Announces Promising Results From IPLEX Phase II Myotonic,Muscular Dystrophy Clinical Study 3Insmed Announces Promising Results From IPLEX Phase II Myotonic,Muscular Dystrophy Clinical Study 4Novavax Reports Positive Pre-Clinical Study Results from Live Virus,Challenge to Pandemic Flu Vaccine 2Novavax Reports Positive Pre-Clinical Study Results from Live Virus,Challenge to Pandemic Flu Vaccine 3
Disposable Microscissors: Horizontal, Straight...
Low profile, sharp-tipped scissors with a vertical cutting action. Excellent for peeling and cutting fine epiretinal membranes....
... original and very popular 1286 ... cutting in the vertical plane ... tips allow greater versatility when ... Tip is shaped like pic ...
Claes Shielded Retinotomy Scissors, Curved Vertical...
Medicine Products: